Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis

Inclusion Criteria:

Subjects has a diagnosis of psoriatic arthritis (by the Classification of Psoriatic
Arthritis criteria (CASPAR), with ≥ 3 tender and ≥ 3 swollen joints (excluding distal
interphalangeal joints). Subjects must have at least

1 psoriatic skin lesion. Exclusion Criteria:

• -Subject has known history of active tuberculosis.

- Subject has a planned surgical intervention between baseline and the week 52
evaluation.

- Subject has an active infection or history of infections.

- Subject has any systemic disease (eg, renal failure, heart failure, hypertension,
liver disease, diabetes, anemia) considered by the Investigator to be clinically
significant and uncontrolled.

- Subject has any concurrent medical condition or electrocardiogram (ECG) abnormality
that, in the opinion of the investigator, could cause this study to be detrimental to
the subject.

Subject has severe depression measured by Personal Health Questionnaire Depression Scale
(PHQ-8) or suicidal ideation/behavior as measured by and Columbia Suicide Severity Rating
Scale (e-CSSRS)

• Subject has a history or evidence of psychiatric disorder or substance abuse considered
by the Investigator to pose a risk to subject safety